Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00408005 · OUTCOME

Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort

Combination Chemotherapy in Treating Young Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or T-cell Lymphoblastic Lymphoma · Source last updated 2026-06-23

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
percent probability
Interval / dispersion
95% Confidence Interval
Time frame
4 years from end of induction

What was measured

Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.

Analysis population: Includes T-cell lymphoblastic lymphoma (T-LLy) patients that are standard risk, high risk and induction failures. All Standard risk T-LLy patients only received Arm I. Induction failures were assigned to Arm II.

Groups in this outcome

ARM I (Combination Chemotherapy)

No Nelarabine, Capizzi Methotrexate

ARM II (Combination Chemotherapy)

Nelarabine, Capizzi Methotrexate

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
ARM I (Combination Chemotherapy)143
ARM II (Combination Chemotherapy)62

Reported measurements

Standard Risk

Analysis denominator · Participants

GroupSource count
ARM I (Combination Chemotherapy)82
ARM II (Combination Chemotherapy)0
Values in percent probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
ARM I (Combination Chemotherapy)87.4Not reported79.695.2Not reported
High Risk

Analysis denominator · Participants

GroupSource count
ARM I (Combination Chemotherapy)61
ARM II (Combination Chemotherapy)60
Values in percent probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
ARM I (Combination Chemotherapy)85.1Not reported75.794.5Not reported
ARM II (Combination Chemotherapy)85.0Not reported75.095.0Not reported
Induction Failure

Analysis denominator · Participants

GroupSource count
ARM I (Combination Chemotherapy)0
ARM II (Combination Chemotherapy)2
Values in percent probability · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
ARM II (Combination Chemotherapy)100Not reported100100Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        79.6
        upper Limit
        95.2
        value
        87.4
    denoms
    1. counts
      1. group Id
        OG000
        value
        82
      2. group Id
        OG001
        value
        0
      units
      Participants
    title
    Standard Risk
  2. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        75.7
        upper Limit
        94.5
        value
        85.1
      2. group Id
        OG001
        lower Limit
        75.0
        upper Limit
        95.0
        value
        85.0
    denoms
    1. counts
      1. group Id
        OG000
        value
        61
      2. group Id
        OG001
        value
        60
      units
      Participants
    title
    High Risk
  3. categories
    1. measurements
      1. group Id
        OG001
        lower Limit
        100
        upper Limit
        100
        value
        100
    denoms
    1. counts
      1. group Id
        OG000
        value
        0
      2. group Id
        OG001
        value
        2
      units
      Participants
    title
    Induction Failure
denoms
  1. counts
    1. group Id
      OG000
      value
      143
    2. group Id
      OG001
      value
      62
    units
    Participants
description
Disease Free Probability where DFS time is defined as time from randomization end of induction to first event (relapse, second malignant neoplasm, death) or date of last contact for patients who are event-free.
dispersion Type
95% Confidence Interval
groups
  1. description
    No Nelarabine, Capizzi Methotrexate
    id
    OG000
    title
    ARM I (Combination Chemotherapy)
  2. description
    Nelarabine, Capizzi Methotrexate
    id
    OG001
    title
    ARM II (Combination Chemotherapy)
param Type
NUMBER
population Description
Includes T-cell lymphoblastic lymphoma (T-LLy) patients that are standard risk, high risk and induction failures. All Standard risk T-LLy patients only received Arm I. Induction failures were assigned to Arm II.
reporting Status
POSTED
time Frame
4 years from end of induction
title
Disease-free Survival (DFS) for T-cell Lymphoblastic Lymphoma (T-LLy) Cohort
type
PRIMARY
unit Of Measure
percent probability

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice